BTK and mantle cell lymphoma: High Btk expression is well established in B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL); inhibition of Btk-signaling pharmacologically by FDA-approved Btk inhibitor, ibrutinib, has been shown to be effective in managing these diseases [7, 15].